Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

87.50 +1.10 (+1.27%)
Official Closing Price Updated: 4:10 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
From Merck & Co., Inc.
Via Business Wire
Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug
Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025. 
Via Benzinga
Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda
Via Stocktwits
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Via Stocktwits
Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50
Via Stocktwits
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
Decoding Merck & Co's Options Activity: What's the Big Picture?
 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
From Merck & Co., Inc.
Via Business Wire
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,... 
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots
Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days... 
Via Benzinga
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances
Discover Merck & Co. (MRK), a top value stock with strong profitability, sound financial health, and an attractive valuation. A prime pick for value investors. 
Via Chartmill
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
From Daiichi Sankyo
Via Business Wire
2 Healthcare Dividend Stocks to Buy and Hold
These drugmakers have competitive yields and have increased their dividends at a good clip. 
Via The Motley Fool
Topics Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen
Discover Merck & Co. (MRK), a top-tier stock excelling in profitability, high ROIC, strong cash flow, and a robust balance sheet for long-term quality investing. 
Via Chartmill
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen. 
Via Benzinga
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial. 
Via Benzinga
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
1 Profitable Stock to Own for Decades and 2 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Economy
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds. 
Via Benzinga
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial... 
Via Benzinga
Topics Government
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space? 
Via The Motley Fool
Topics Intellectual Property
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.